ASCO: Overall Survival Up for African-American Men With mCRPC
Improved survival versus Caucasian men treated with docetaxel/prednisone, DP-containing regimen
THURSDAY, June 7, 2018 (HealthDay News) -- Overall survival is increased for African-American men with metastatic castration resistant prostate cancer (mCRPC) versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen, according to a study presented at the annual meeting of the American Society for Clinical Oncology, held from June 1 to 5 in Chicago.
Susan Halabi, Ph.D., from the Duke University Medical Center in Durham, N.C., and colleagues combined individual patient data from 8,820 mCRPC patients randomized on nine phase III trials to DP or a DP-containing regimen. Overall survival was assessed as the primary end point, and was compared for 7,528 Caucasian patients and 500 African-American patients.
The researchers found that the median overall survival was 21.0 months in African-American patients and 21.2 months in Caucasian patients. After adjustment for established risk factors, in multivariable analysis, the pooled hazard ratio for African-Americans versus Caucasians was 0.81 in all patients. The results were similar for the 4,172 patients treated with DP.
"This study underscores the importance of increasing the participation of racial minorities in clinical trials," Halabi said in a statement. "Every patient who participates in a clinical trial contributes to improving care, and all patients should have the opportunity to receive needed therapies."